Business
ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada
ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada\n\nViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada\n\n\nThe Company Plans to Sell its Products Through a Distributor with over 400 Retail Stores Who Currently are Selling Medical (MMJ) and Associated Cannabinoid Products that are Accepted and Allowed, and an on-line store via the Web\n\n LOS ANGELES, CA--(Marketwired - September 08, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko is working a distribution deal to distribute its Patent Pending products to over 400 retail dispensary outlets in Canada. The Company would combine its Patent pending MMJ technology Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The Management Company plans to launch 3 products in the form of a spray application, a roll on application and an ointment application. The Company plans to continue to expand its (IP) \"Intellectual Property Portfolio\" in 2017 & 2018, adding multiple products, including a patch for treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. \"Unlike other similar products on the market, what makes our world class product line unique is having the % of CBD/THC listed on our products, and with our patent pending delivery system we will have more than 95% of the active ingredients absorbed into the skin. Similar competing products have an absorption rate of 5-30%, and often not tested or listed at all,\" Otiko said. Earlier this year the Company had signed a formal agreement based on its' initial LOI to work with a Canadian group with expertise in logistics that includes distribution for the new and anticipated products. The Management Company is working closely with ViaDerma and is developing multiple key pr...